Cardiology Associations

This page includes news coverage of cardiology societies and associations. Follow these links for specific cardiology society news pages: American College of Cardiology (ACC), American Heart Association (AHA), American Society of Echocardiography (ASE), American Society Nuclear Cardiology (ASNC), European Society of Cardiology (ESC), Heart Rhythm Society (HRS), Society for Cardiovascular Angiography Interventions (SCAI), Society of Cardiovascular Computed Tomography (SCCT), Transcatheter Cardiovascular Therapeutics (TCT), and Vascular Interventional Advances (VIVA).

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years
PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.
CRF merges with Fogarty Innovation to take healthcare innovation to the next level
The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco.
A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025
The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.
Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems
The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.
'The less you drink, the better': Even minor changes in alcohol use lower hypertension risk
These new findings challenge the long-standing assumption that low levels of alcohol do not meaningfully influence a person's blood pressure.

Michael J. Mack, MD, discusses his team's seven-year update to the PARTNER 3 trial at TCT 2025 in San Francisco.

PARTNER 3 update: TAVR still comparable to SAVR in low-risk patients after 7 years

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025.

Cardiovascular Research Foundation is merging with Fogarty Innovation

CRF merges with Fogarty Innovation to take healthcare innovation to the next level

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco.

Christian M. Spaulding, MD, PhD, at TCT 2025

A promising SELUTION: Sirolimus-eluting balloon from Cordis makes impression at TCT 2025

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed.

Medtronic launches FDA-cleared guidewire compatible with multiple TAVR systems

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.

'The less you drink, the better': Even minor changes in alcohol use lower hypertension risk

These new findings challenge the long-standing assumption that low levels of alcohol do not meaningfully influence a person's blood pressure.

New biodegradable PFO closure device shows early potential

Researchers tracked patients for two years, using echocardiography to confirm the devices had completely vanished. Additional studies will still be required.

potential new tariffs on medical devices, imaging equipment, PPE and more

Cardiology groups among the voices concerned about more medical device tariffs

When the Trump administration requested public input on adding more tariffs for PPE and all medical devices, hundreds of public comments were submitted. One common concern among those responses is that healthcare providers could be left with significantly higher costs.

American Society of Nuclear Cardiology (ASNC) President-elect Jamieson M. Bourque, MD, MHS, FASNC, medical director of nuclear cardiology, echocardiography, and the stress laboratory at UVA Health in Charlottesville, and a professor of medicine and radiology at the University of Virginia, explains some of the new things ASNC will be doing in 2026

Collaborations, guidelines and grants: ASNC shares big plans for 2026

American Society of Nuclear Cardiology President-elect Jamieson M. Bourque, MD, detailed just some of what the group has planned for 2026. For example, ASNC will be working on the development of multiple new guidelines designed to help clinicians provide high-quality care.